Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ⅱ, First-in-Human Study of XNW27011 in Patients With Locally Advanced and/or Metastatic Solid Tumors

NCT06792435 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT06792435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06792435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ⅱ, First-in-Human Study of XNW27011 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 27, 2023
Completion date
June 30, 2027
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, colorectal cancer metastatic, gastric carcinoma, gastroesophageal junction adenocarcinoma, lung cancer (nsclc), ovarian cancer, pancreatic adenocarcinoma metastatic